oral+semaglutide+approval Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral semaglutide (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Wegovy Pill Gets FDA Approval

[2] [5] NICE guidance emphasises that pharmacological interventions like Mounjaro should be integrated within a comprehensive approach that includes dietary modification, increased physical activity, and behavioural support

134 Therefore, an assessment of the degree of liver injury is usually advisable

Compared with the lowest quartile, hazard ratio (95% CI) of the highest quartile was 2.47 (1.48-4.14) for FIX, 1.37 (0.85-2.20) for FVIII, 1.11 (0.76-1.63) for FXI, 0.98 (0.65-1.48) for fibrinogen, 1.56 (1.07-2.28) for ETP, 1.84 (1.23-2.74) for peak, 1.59 (1.08-2.33) for velocity, 0.92 (0.62-1.38) for lag time, and 1.21 (0.86-1.70) for time-to-peak

Provides Powerful Antioxidant Protection High-potency antioxidants help reduce oxidative stress and protect cells from damage

Does Ozempic cause heart palpitations